Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-2141 tablets (I) and (II), which will commence shortly [1] Group 1 - HRS-2141 tablets (I) and (II) are fixed-dose combination formulations designed to synergistically lower blood glucose through complementary pharmacological mechanisms [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - As of the date of the announcement, the cumulative research and development investment for this drug project is approximately 5.4 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS-2141 tablets (I) and (II), which will commence shortly [1] Group 1: Product Development - HRS-2141 tablets (I) and (II) are fixed-dose combination formulations designed to synergistically lower blood sugar through complementary pharmacological mechanisms [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - As of the date of the announcement, the cumulative research and development investment for this drug project amounts to approximately 5.4 million yuan (unaudited) [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of HRS-2141 tablets for type 2 diabetes [1] Group 1: Company Announcement - Jiangsu Heng Rui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Medicine Co., Ltd., has been granted a clinical trial approval notice for HRS-2141 tablets (I) and (II) [1] - The approval allows the company to conduct clinical trials for the drug targeting type 2 diabetes [1] - The acceptance numbers for the clinical trial applications are CXHL2501153 and CXHL2501154 [1] Group 2: Regulatory Details - The approval conclusion states that HRS-2141 tablets (I) and (II) meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] - The clinical trials are set to commence following the approval, which was granted based on a review conducted on October 21, 2025 [1]